MetaCap

Senseonics Holdings Inc. (SENS)

NASDAQ: SENSHealth CareMedical/Dental InstrumentsUSD

8.02-0.885 (-9.94%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SENS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$439.34M
EPS (TTM)
-$2.27
52-week range
4.79 – 13.98
Day range
7.93 – 8.95
Volume / Avg
1.39M / 821.73K
Beta
—

52-week range

$4.79$13.98

SENS stock today

On Nov 20, SENS ended the session at $8.02, shedding $0.885 (9.94%), versus the S&P 500's 3.70% decline. Shares are 42.6% below their 52-week high of $13.98, set on Nov 10, 2026 and 67.4% above the 52-week low of $4.79, in the middle of the past year's range. SENS is up 45.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 49.9%.

Senseonics has posted a net loss over the last twelve months (EPS of -$2.27), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Senseonics

Company profile

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.

Industry
Medical/Dental Instruments
CEO
Dr. Timothy T. Goodnow Ph.D.
Headquarters
Germantown, MD
Employees
130

Financial highlights

Full financials

In fiscal 2025, Senseonics generated $35.3 million in revenue, up 56.9% from fiscal 2024, its 5th consecutive year of revenue growth. Senseonics reported a net loss of $69.1 million, compared with a loss of $78.6 million a year earlier. Gross margin was 44.7% (up from 2.4%) and operating margin -193.8%.

Senseonics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$35.26M$22.47M$22.39M$16.39M$13.68M
Growth+56.89%+0.37%+36.62%+19.85%+176.32%
Net income$-69.10M$-78.60M$-60.40M$142.10M$-302.47M
EPS (diluted)$-1.66$-2.50$-0.11$-0.11$-0.72

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$15.08+88.03%

  • Strong buy 0
  • Buy 4
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.43 vs $-0.49
Surprise
+12.24%

SENS news

All SENS news

Senseonics peers

Health Care sector
SENS peer companies
CompanyPrice% ChgMarket capCompare
MDXGMiMedx Group Inc3.05-1.93%$445.07Mvs SENS
ANGOAngioDynamics Inc.10.81+0.46%$454.61Mvs SENS
SIShoulder Innovations Inc.20.15-0.79%$421.58Mvs SENS
CARLCarlsmed Inc.17.42+1.16%$477.38Mvs SENS
MOBIMobia Medical Inc.11.85-0.08%$394.50Mvs SENS
RCELAvita Medical Inc.15.62-2.31%$494.96Mvs SENS
CERSCerus Corporation1.85-2.63%$373.62Mvs SENS
BWAYBrainsWay Ltd. ADR8.48-2.86%$341.35Mvs SENS

Indexes, lists and sector

Senseonics stock FAQ

What is Senseonics's stock price today?

SENS last traded at $8.02 as of Nov 20, 4:00 PM EST, down 9.94% on the day. Prices are delayed at least 15 minutes.

Does Senseonics pay a dividend?

No. Senseonics does not currently pay a regular cash dividend.

Who is Senseonics's CEO?

Dr. Timothy T. Goodnow Ph.D. is the chief executive officer of Senseonics Holdings Inc., which has about 130 employees.

Has SENS ever split its stock?

Yes. The most recent SENS stock split was a 1-for-20 split on Oct 20, 2025.

What is the SENS 52-week high?

The 52-week high for SENS is $13.98 and the 52-week low is $4.79. The stock is currently 42.6% below its high.

Compare SENS